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Abstract 
Immune thrombocytopenia (ITP) is an autoimmune disorder, characterised by an isolated 
low platelet count. Genes influencing activation of the immune system have been identified 
as influencing predisposition. Killer cell immunoglobulin-like receptors (KIR) control T-cell 
and Natural Killer cell function via inhibitory and activating signalling pathways. The 
inhibitory KIR2DL3, KIR3DL2 and KIR3DL1 are up-regulated in the T-cells of patients with 
ITP in remission relative to those with active disease, and an association of 
KIR2DS2/KIR2DL2 with ITP has also been reported. No comprehensive genotypic KIR 
analysis in ITP has been reported. We performed genotyping of all currently known KIR 
genes using sequence specific primer polymerase chain reaction (SSP-PCR) on a cohort 
of 83 adult patients with ITP (chronic/persistent or relapsed primary ITP identified by 
standard criteria) and 106 age matched healthy white volunteers. Non-white patients were 
not included in the analysis. There was an over-representation of KIR2DS3 (known to be 
in linkage disequilibrium with KIR2DS2/2DL2) and under-representation of KIR2DS5 (also 
protective against other immune mediated disorders) in adult ITP (odds ratio 0.16, C.I. 
0.08-0.32, P<0.001). By multivariable binary logistic regression to adjust for age, sex and 
the effects of other KIR genes, the presence of KIR2DS2/2DL2 with KIR2DS5 abrogated 
the risk of KIR2DS2/2DL2 and the protective benefit of KIR2DS5. Further studies are 
required to establish the mechanistic basis for these observations and their potential 
impact on ITP therapy.  
 2 
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published 
or written by another person except where due reference has been made in the text. I 
have clearly stated the contribution by others to jointly-authored works that I have included 
in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional 
editorial advice, and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of 
my research higher degree candidature and does not include a substantial part of work 
that has been submitted to qualify for the award of any other degree or diploma in any 
university or other tertiary institution. I have clearly stated which parts of my thesis, if any, 
have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University 
Library and, subject to the policy and procedures of The University of Queensland, the 
thesis be made available for research and study in accordance with the Copyright Act 
1968 unless a period of embargo has been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the 
copyright holder(s) of that material. Where appropriate I have obtained copyright 
permission from the copyright holder to reproduce material in this thesis. 
 
 3 
Publications during candidature 
Related to thesis: 
Peer reviewed papers: 
1. Seymour LA, Nourse, JP, Crooks P, Wockner L, Bird R, Tran H and Gandhi MK. The 
presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue 
Antigens. 2014. 83(3)154-160. 
 
Conference Abstracts: 
1. Seymour L, Nourse JP, Crooks, P, Wockner L, Bird R, Tran H and Gandhi MK. The 
presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Oral 
Presentation and Runner-up award. Haematological Society of Australia and New Zealand 
Scientific Meeting (Oct 2013) 
 
Unrelated to thesis: 
Peer reviewed papers: 
1. Jones KL, Vari F, Keane C, Crooks P, Nourse JP, Seymour LA, et al. Serum CD163 
and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clin. 
Cancer Res. 2012 Dec 5; 
Book chapters: 
1. Jones K, Seymour L, Gandhi MK. CD163 and TARC as Disease Response Biomarkers 
in Hodgkin Lymphoma. In: Preedy VR, Patel VB (eds). Cancer. Biomarkers in Disease: 
Methods, Discoveries and Applications, vol 2. Springer, Dordrecht. 2015. 
 
Conference Abstracts: 
1. Jones KL, Vari F, Keane C, Crooks P, Nourse JP, Seymour LA, et al. Serum CD163 
and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. Oral 
Presentation, American Society of Hematology 54th Annual Meeting (Dec 2012). This work 
was also presented at the Highlights of ASH in North America (Feb 2013) and the 
Highlights of ASH in Asia (March 2013) 
 
 
 
 
 
 
 4 
 
Publications included in this thesis 
 
Seymour LA, Nourse, JP, Crooks P, Wockner L, Bird R, Tran H and Gandhi MK. The 
presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue 
Antigens. 2014. 83(3)154-160 – incorporated as Appendix 1.  
 
Contributor Statement of contribution 
Author LAS(Candidate) Designed experiments (70%) 
Performed experiments (70%) 
Analysed data (60%) 
Wrote the manuscript (70%) 
Author JPN Designed experiments (30%) 
Analysed data (15%) 
Author PC Performed experiments (30%) 
Author RB Wrote the manuscript (10%) 
Facilitated sample collection 
Author MKG Analysed data (15%) 
Wrote the manuscript (20%) 
Author LW Performed statistical analysis for Tables  
Author HT Facilitated sample collection 
 
 
 5 
Contributions by others to the thesis  
 
My supervisors, Professor Maher Gandhi and Associate Professor Robert Bird, contributed 
significantly to conception of the projects described in this thesis. No other significant 
contributions were made. 
 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
 
No part of this work has not been contributed towards another degree. 
 6 
Acknowledgements 
 
Pathology Queensland assisted with funding for the laboratory analysis, and Roche 
Products Pty Ltd (Australia) provided a research grant for the coordination of sample 
assays as a sub-study of clinical trial protocol ML20948. 
 
Other thanks go to my advisory team, Professor Maher K. Gandhi and Associate professor 
Robert Bird as well as members of the laboratory including: 
 
Dr Jamie Nourse 
Mrs Pauline Crooks 
Dr Devinder Gill 
Dr Robert Bird 
Dr Huyen Tran 
Dr Frank Vari 
Dr Qingyan Cui 
Dr Colm Keane 
 
Statistical support was provided by Dr Leesa Wockner who provided invaluable guidance 
and assistance in the application and interpretation of all statistical test performed. 
 
 7 
Keywords 
Immune thrombocytopenia, killer cell immunoglobulin-like receptor, KIR2DS5, platelets, 
genotype, protection 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
 
ANZSRC code: 110706 Immunogenetics (incl. Genetic Immunology) 60% 
ANZSRC code 110202 Haematology  20% 
ANZSRC code: 110703 Autoimmunity 20% 
 
Fields of Research (FoR) Classification 
 
FoR code: 1107 Immunology, 80% 
FoR code: 1102 Cardiorespiratory Medicine and Haematology,  20% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
Table of Contents 
 
List of Figures and Tables.................................................................................................9 
Abbreviations……………………………………………………………………………………..10 
1. Review of the Literature……………………………………………………………….12 
1.1 Epidemiology, diagnosis and classification of ITP………………………..12 
1.2 Pathogenesis of ITP…………………………………………………………. 13 
1.3 Genetics of ITP (FCGR family polymorphisms)………………………….. 18 
1.4 Killer immunoglobulin-like receptors (KIR)………………………………... 20 
1.5 KIRs and ITP…………………………………………………………………. 22 
2.  Hypothesis and Aims…………………………………………………………………...23 
3.  Methodology…………………………………………………………………………….. 24 
3.1 Patients/Healthy Volunteers…………………………………………………… 24 
3.2 SSP-PCR……………………………………………………………………….... 25 
3.3 HLA-allotyping…………………………………………………………………... 26 
3.4 Statistics………………………………………………………………………...... 26 
4.  Results…………………………………………………………………………………… 27 
4.1 Study population………………………………………………………………… 27 
4.2 Genotype and allele frequencies………………………………………………. 27 
4.3 KIR haplotypes…………………………………………………………………… 31 
4.4 Compound Genotypes.…………………………………………………………..32 
4.5 HLA-C allotypes…………………………………………………………………..33 
5.  Discussion……………………………………………………………………………….. 33 
6.  References……………………………………………………………………………….. 36 
Appendix A………………………………………………………………………………………. 48 
 
 
 
 
 
 
 
 
 
 
 9 
 
List of Figures and Tables 
Table 1. First line investigations recommended when diagnosing ITP. 
Table 2. KIR molecules and HLA ligands. 
Table 3. Primer combinations used in the KIR PCRs. 
Table 4. Set specific thermocycling conditions. 
Table 5. Distribution of genes amongst the cases and controls with accompanying 
unadjusted odds ratios.  
Table 6.  Test of association between presence and absence of KIR2DS2 in both cases 
and controls. 
Table 7. Unadjusted and adjusted (for age and sex) odds ratios for a multivariable binary 
logistic regression containing KIR2DL2/KIR2DS2 and KIR2DS5. 
Table 8. Unadjusted and adjusted (for age and sex) odds ratios for a binary logistic 
regression containing haplotype B/- . 
Table 9. Confidence intervals for the combinations of 2DS2/2DL2 compound genotype 
and 2DS5. 
Figure 1. Graphical representation of currently accepted pathophysiological mechanisms 
in ITP. 
Figure 2. Schematic representation of KIR haplotypes on the KIR gene locus. 
Figure 3. An example of an agarose gel demonstrating the distinct bands of KIR3DS1 and 
KIR2DL2. 
Figure 4. Odds ratio of KIR genotypes in patients versus controls.  
Figure 5.  Linkage disequilibrium plot demonstrating LD between KIR subtypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
Abbreviations 
ITP  Immune thrombocytopenia 
HIV  Human immunodeficiency virus 
HCV  Hepatitis C virus 
ANA  Antinucleotide antibody 
IVIg  Intravenous immunoglobulin 
H.pylori Helicobacter pylori 
IgG  Immunoglobulin G 
gp  Glycoprotein 
AIHA  Autoimmune haemolytic anaemia 
Rh  Rhesus 
APC  Antigen presenting cell 
TPO  Thrombopoietin 
CD  Cluster differentiation 
MAB  Monoclonal antibody 
CTL  Cytotoxic T lymphocyte 
IL  Interleukin 
IFN  Interferon 
Th  T helper 
Treg  Regulatory T-cell 
IPEX  Immunodysregulation polyendocrinopathy enteropathy X-linked 
BAFF  B-cell activating factor 
SLE  Systemic lupus erythematosus 
NK  Natural killer 
FCGR  FC gamma receptor 
ITAM  Intracellular tyrosine-based activation motif 
ITIM  Intracellular tyrosine-based inhibition motif 
SNP  Single nucleotide polymorphism 
ADCC  Antibody dependent cellular cytotoxicity 
OR  Odds ratio 
P  p-value 
DNA  Deoxyribonucleic acid 
RNA  Ribonucleic acid 
miR  Micro RNA 
KIR  Killer cell immunoglobulin-like receptor 
 11 
HLA  Human leukocyte antigen 
ALL  Acute lymphoblastic leukaemia 
CML  Chronic myeloid leukaemia 
TKI  Tyrosine kinase inhibitor 
IWG  International working group 
PCR  Polymerase chain reaction 
SSP-PCR Sequence specific primer PCR 
SSOP-PCR Sequence specific oligonucleotide PCR 
KCl  Potassium chloride 
dNTP  deoxy nucleotide triphosphate 
MgCl2  Magnesium chloride 
C.I.  Confidence interval 
LD  Linkage disequilibrium 
NS  Not significant 
TCR  T-cell receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
1.  Review of the Literature 
 
1.1 Epidemiology, diagnosis and classification of ITP. 
 
Immune thrombocytopenia (ITP), previously known as idiopathic thrombocytopenic 
purpura, is best defined as an acquired isolated thrombocytopenia without known 
underlying precipitating factors1. ITP occurs in both adults and children without any 
observable ethnic predilection, however there are age related differences in disease 
manifestation and management. Paediatric ITP usually follows a viral infection and 
although the thrombocytopenia can be marked, it is rarely associated with serious bleeding 
and often spontaneously resolves. Adult ITP has an incidence of 2.6-6.6 per 100 000 
adults per year and a mortality rate of 1-4% per year2. ITP can be further subclassified into 
primary (occurring in isolation, ~80% of cases) or secondary (associated with a defined 
underlying disorder, ~20% of cases). Secondary ITP is often associated with autoimmune 
disorders, malignancy, infections3 and certain drugs suggesting that ITP is a result of 
diverse mechanisms such as co-existing immune dysregulation and molecular mimicry 
after infection. The phases of ITP are currently classified as: newly diagnosed (up to 3 
months from diagnosis), persistent (3-12 months from diagnosis) and chronic (>12 months 
since diagnosis)4. The clinical course of ITP is unpredictable, with no single therapy 
considered to be ‘gold standard’. Many patients with ITP are minimally symptomatic 
however there is a subset of patients who present with severe bleeding. The morbidity of 
ITP is based principally on the presence of bleeding, however studies have demonstrated 
that patients with ITP are also at increased risk of infection, thrombosis and haematologic 
malignancies2.  
 
In practice, a diagnosis of ITP is made in the setting of isolated thrombocytopenia 
following exclusion of other causes of thrombocytopenia. Appropriate first line 
investigations and other clinical considerations are outlined in table 1. 
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Table 1: First line investigations recommended when diagnosing ITP5 
First line investigations: 
Exclude exposure to heparin (e.g. recent surgery) and haematinic 
deficiencies. 
Review of the peripheral blood count and film – exclude other abnormalities 
including other causes of thrombocytopenia, for example dysplastic features 
would implicate myelodysplasia1. 
Liver function testing and coagulation profile – exclude liver disease and 
consumptive coagulopathy as a cause of thrombocytopenia. 
Test for HIV and HCV, ANA and Lupus anticoagulant1 
Helicobacter Pylori*, particularly in patients in whom eradication would be 
used if testing was positive1. Note: serology may be falsely positive after 
intravenous immunoglobulin (IVIg). 
No longer advised: 
Bleeding Time (poor sensitivity and specificity). 
Platelet autoantibody testing (poor sensitivity and specificity). 
 
*H.pylori eradication has been shown to be successful in certain populations with a high 
incidence of H.pylori (e.g. Japanese) and less successful in western populations. For a 
review of H.pylori and ITP see the review by Stasi et al.6 
 
1.2 Pathogenesis of ITP 
 
The currently understood mechanisms involved in the pathophysiology of ITP are 
incompletely understood and multifactorial and considered primarily as a result of a 
dysregulated immune system. These are illustrated in figure 1.  
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Figure 1. Graphical representation of currently accepted pathophysiological mechanisms in ITP. In antibody 
mediated destruction, T cells regulate the development of a limited number of B cell autoreactive clones 
which in turn develop into plasma cells. These secrete IgG autoantobodies directed against platelet surface 
glycoproteins, resulting in platelet destruction in the reticulo-endothelial system. Impaired megakaryopoiesis 
as an independent multifactorial mechanism as described on page 15, also contributes to the development 
of ITP. 
Antibody mediated platelet destruction is the most widely accepted mechanism in 
ITP. This was first demonstrated in 1951 when James Harrington self-injected 500mL of 
blood from a patient with ITP. Within 3 hours his platelet count dropped below 10x109/L 
and he developed petechiae and suffered a seizure. He later repeated the experiment on 
“all suitable staff from the Barnes Jewish Hospital” and together with Hollingsworth 
published the first report of a “thrombocytopenic factor” in the blood of patients with 
thrombocytopenic purpura7. Since then it has been shown that ITP occurs as a result of 
predominantly IgG antibody-mediated platelet destruction and variably impaired platelet 
production with the most common antigenic targets being platelet surface glycoproteins, 
gpIIb/IIIa8, with other platelet surface antigens also implicated in a minority of cases9. The 
IgG antibodies directed against these glycoproteins appear to be derived from a limited 
number of B-cell clones10. Platelet destruction in ITP is generally considered to be 
primarily due to platelet opsonisation which not only results in accelerated clearance by 
macrophage mediated  phagocytosis but may also affect platelet function and platelet 
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production11. Of note, anti-platelet antibodies are only detected in up to 60% of patients11. 
This is likely due to a combination of limited assay sensitivity and variability of epitopes. It 
has yet to be established why some individuals develop these anti-platelet auto antibodies 
to several structurally diverse platelet proteins. Unlike in warm autoimmune haemolytic 
anaemia (AIHA) where antibodies are often confined to epitopes within the Rh locus, in 
ITP, the proposed mechanism involves a 2-step process. Opsonisation of platelets by 
antibodies against surface proteins is followed by phagocytosis by antigen presenting cells 
(APC)s.  Subsequent proteosomal degradation results in the formation and presentation of 
novel epitopes often derived from cytoplasmic proteins12.  
 
It has recently been demonstrated that reduced megakaryocytes and impaired 
megakaryopoiesis, is a significant factor in the development of thrombocytopenia. This 
was demonstrated by Louwes et al12 by performing platelet kinetic studies using indium-
111-labelled autologous platelets and clearly demonstrated a combination of both reduced 
platelet production and reduced platelet lifespan. Platelet production by megakaryocytes is 
regulated by thrombopoietin (TPO) which is constitutively synthesized in the liver and 
circulates to the bone marrow, where it binds TPO receptors (cMPL) on early 
megakaryocyte progenitors thereby stimulating their proliferation and differentiation. TPO 
also binds to circulating platelets, which reduces the TPO available to stimulate 
megakaryocytes, thus low platelet counts enable more TPO to reach the marrow to 
increase megakaryopoiesis. Paradoxically in ITP, serum TPO is not increased. The 
mechanistic basis for this observation remains to be elucidated but is postulated to be due 
to TPO clearance along with antibody-coated platelets. In ITP, there are no consistent 
morphological changes in megakaryocytes demonstrable morphologically however they 
may lack granularity, have reduced ploidy and may have fewer platelets budding from 
plasma membranes. Megakaryocyte apoptosis, due to increased caspase 3, has been 
reported, as well as fragments from degenerating megakaryocytes being phagocytosed by 
macrophages and neutrophils13. It has recently been appreciated that these 
megakaryocyte changes are likely due to autoantibody mediated mechanisms. Not only do 
megakaryocytes express platelet glycoproteins during their development making them 
targets of ITP antibodies, but some auto antibodies preferentially recognise 
megakaryocyte epitopes14. A study by McMillan et al.15 showed that plasma (and IgG 
fractions) from patients with ITP suppressed in vitro megakaryocyte production from 
CD34+ progenitor cells and reduced megakaryocyte ploidy. Unfortunately little is known 
about the potential effects of ITP antibodies on downstream platelet development.   
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Mechanisms of platelet clearance in ITP involve splenic and liver clearance by Fcγ 
receptors, with a number of conventional treatment modalities (IVIG, anti-D, steroids and 
anti-CD20 monoclonal antibodies (MABs) inhibiting antibody-mediated platelet clearance 
at the Fcγ receptor. Other additional platelet clearance pathways may include complement 
mediated pathways (some ITP antibodies fix C3b to platelets)16 and expression of P-
selectin and phosphatidylserine associated with GP1b clustering platelet destruction 
signal17. 
 
The role of T-cell mediated cytotoxicity towards platelets and platelet precursors is 
also under investigation as a component of the pathogenesis of ITP. This has been 
postulated as a contributing mechanism based on the data of Roark et al10 where it was 
shown that platelet specific antibodies derived from patients with ITP had restricted heavy 
chain rearrangement consistent with derivation from a single B-cell clone and somatic 
mutation in heavy and light-chain variable regions which is consistent with a classical T-
cell dependent antigen-driven immune response. There is also a likely contribution from 
cytotoxic T-cell (CTL) direct lysis of platelets18,19 and accumulation of CTLs in the bone 
marrow sufficient to disrupt thrombopoiesis20.  
 
Studies of cytokine profiles in chronic ITP also point towards a skewed T-cell 
response with increased IL-2 and IFN-γ, reduced IL-4 and IL-10, and decreased TGF-β 
consistent with a Th-0/Th-1 response21,22. This pattern of cytokines is associated with the 
differentiation and maturation of autoreactive B-cells into autoantibody producing plasma 
cells and the development of CTLs. Another study demonstrated that Th1/Th2 mRNA ratio 
was inversely correlated with the platelet count in adult patients with ITP which also infers 
a polarised Th1 response23. It has been postulated that this predominantly Th1 response in 
ITP is likely due to reduced numbers of circulating Th2 cells or the number and/or function 
of (CD4+/CD25(bright)/FOXP3+) regulatory T-cells (Tregs)24. 
 
Tregs are derived via two distinct pathways, thymus-derived Tregs and peripherally 
(or adaptive) derived Tregs which arise from naïve CD4+ T-cells encountering self-
antigens25. The role of the Treg is to limit autoimmune responses and assist in the 
maintenance of self-tolerance26. Genetic deficiencies of Tregs are associated with diverse 
autoimmune type presentations such as IPEX syndrome in humans27 and Scurfy in mice28. 
The contribution of reduced numbers of Tregs in the pathophysiology of ITP is still unclear. 
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Nishimoto et al. have shown that one third of nude mice, when reconstituted with Treg 
depleted T-cells developed antibody-mediated thrombocytopenia29. It has also been 
observed that there are reduced numbers and function of Tregs in the peripheral blood of 
patients with ITP (similarly with other autoimmune disorders)30 and it is thought that this 
may contribute towards reduced tolerance and the expansion and differentiation of auto 
reactive B-cells. 
 
Th17 cells are a subset of T-helper cells which produce IL-17 and like Tregs, are 
also derived from undifferentiated naïve CD4+ T-cells31. They have an established role in 
mediating host response to bacterial and fungal infection at mucosal surfaces by triggering 
the release of antimicrobial peptides and recruiting neutrophils. Increased Th-17 cells and 
elevated plasma IL-17 have been demonstrated in adults and children with severe 
autoimmune disease32, including ITP33. The mechanism of IL-17 and Th17 cells in 
autoimmunity still remains to be elucidated.  
 
Tolerance check point defects are also likely to be involved in the immune 
dysregulation associated with ITP. Immune tolerance mechanisms involve the monitoring 
of the lymphocyte repertoire and the induction of anergy in auto reactive lymphocytes. At 
present, it is unclear how immune tolerance is disturbed in primary and secondary ITP. It 
has been postulated by Cines et al.34 that immune tolerance defects in ITP may arise 
during early B-cell development in the bone marrow (central tolerance defects), during 
differentiation with skewed B-cell subsets emerging or in the setting of immune stimulation 
(peripheral tolerance). One immune tolerance homeostasis checkpoint regulator is the 
cytokine B-cell activating factor BAFF which is a member of the tumour necrosis factor 
family and involved in regulating B-cell maturation, survival and immunoglobulin 
production. Thien et al.35 has shown that increased BAFF expression leads to the rescue 
of auto reactive B-cells from anergy and as such, likely has an important role in 
autoimmunity35. In keeping with this theory, Emmerich et al. has shown that there is an 
increased prevalence of the (-871) TT genotype of the BAFF promoter as well as 
increased serum BAFF in ITP36. Elevated BAFF has also been demonstrated in patients 
with other autoimmune diseases such as SLE, rheumatoid arthritis and Sjogren 
syndrome37,38. However, the functional effect of the promoter region polymorphism is yet to 
be established. 
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The role of NK cells in the pathogenesis of ITP is unclear. There are several reports 
of reduced and functionally defective NK cells in ITP39–41 but no definitive mechanism has 
been established. Given the variability in response to rituximab in ITP, further studies are 
warranted to enhance understanding of the role of NK cell function in ITP pathogenesis 
and their impact on rituximab mediated antibody dependent cellular cytotoxicity (ADCC). 
 
1.3 Genetics of ITP  
 
As mentioned above, the primary mechanism of platelet clearance in ITP is due to 
FCγ receptor (FCGR) mediated clearance of opsonised platelets by macrophages. The 
human FCGR family is comprised of three major classes of receptors: FCGR1, FCGR2 
and FCGR3. Each of these arise from multiple transcripts derived from different genes on 
chromosome 1 (FCGR1a and 1b, FCGR2a, 2b and 2c, and FCGR3a and 3b)42. The 
majority of these receptors are involved in signal transduction via an intracellular tyrosine-
based activation motif (ITAM). FCGR2a however expresses an intracellular tyrosine-based 
inhibition motif (ITIM). The FCGR1 subtypes are both high affinity receptors for monomeric 
IgG with the other families being lower-affinity receptors interacting only with complex or 
multimeric IgG43. There is increased heterogeneity within the FCGR subtypes FCGR2a, 3a 
and 3b by functional single nucleotide polymorphisms (SNPs) which appear randomly 
distributed among populations with variable distribution between ethnic groups44,45. It 
appears as though FCGR SNPs may have crucial roles in the phagocytosis of IgG 
opsonised platelets and thus a role in the pathogenesis of ITP. Ghesquieres et al, Bredius 
et al, Sanders et al and Salmon et al have demonstrated that inheritance of higher or lower 
affinity FCGR alleles may be associated with the predisposition towards FCRG related 
immune and infectious diseases46–49.  
 
It has been shown that the FCGR2a-131H (histidine) allele has a higher binding 
affinity for IgG than FCGR2a-131R (arginine)43,50. Other SNPs identified that may be 
relevant in ITP include the FCGR3a-V158 (valine) as opposed to phenylalanine (F) 
polymorphism. IgG1-FCGR3a co-crystallization studies show that FCGR3a interacts with 
the lower hinge region of IgG151 with FCGR3a-158V having a higher IgG1 binding affinity 
than FCGR3a-158F52. It has been hypothesized that the FCGR3a-158V polymorphism is 
associated with enhanced clearing of IgG-platelet complexes by ADCC by both 
macrophages and NK cells. FCGR3a transcripts have been shown to be higher in NK cells 
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from individuals with FCGR3a-158V/V compared with FCGR3a-158V/F or FF genotypes 
with V/V homozygotes having enhanced in vitro ADCC activity53. 
 
Wang et a.54 performed a meta analysis in order to clarify the association between 
FCGR2a H131R polymorphism and ITP54. They found no significant predisposition 
towards ITP in the adult data reviewed and speculated that the conflicting results between 
individual studies were likely a result of ethnic diversity, clinical heterogeneity and small 
sample size. They did, however, find an association in Caucasian children. This was 
originally demonstrated by Carcao et al. in a cohort of 98 predominantly Caucasian 
children in Canada, compared with controls55. This study not only demonstrated an 
association between FCGR2a-131H and ITP but also demonstrated an association with 
FCGR3a-158V alone and in combination with FCGR2a-131H. They did not see any 
association with either of these polymorphisms and the development of chronic ITP. Our 
laboratory has also demonstrated an increased frequency of the FCGR3a-158V/V 
genotype in chronic or relapsed ITP compared with age , sex and ethnicity matched 
controls (OR = 3.05, P = 0.007)56. Other studies57,58, however, did not demonstrate any 
significant difference in FCGR3a-158 polymorphisms which may reflect differences in 
ethnic composition and categorisation of ITP (our study only looked at relapsed and 
chronic ITP, while other studies did not define ITP categories). 
 
The use of the anti-CD20 monoclonal antibody, Rituximab, is widespread in ITP, 
however only a subset of patients will respond and the exact mechanism of action is 
uncertain. Cooper et al.59 demonstrated that a cohort of patients with FCGR3a-158V/V 
polymorphisms were more likely to respond to rituximab. They also demonstrated that non 
responders to rituximab had increased CD8 positive CTLs compared with rituximab 
responders, thus supporting a role for T cell mediated cytotoxicity59. 
 
Other genetic lesions which may be associated with ITP include those in genes 
associated with T-cell activation such as cytokines associated with activation and survival, 
CD72 gene polymorphisms, and DNA hypermethylation of FOXP3 promoter regions 
affecting Treg activity60–66. Micro RNAs have also been investigated and it has been shown 
that increased miR-155 is associated with decreased SOCS1 in ITP. This is thought to be 
associated with regulation of cytokines given that they also demonstrated the negative 
correlation of miR-155 and the cytokines IL-4, IL10 and TGF-β1 levels and the positive 
correlation with IL-17A levels67. Interestingly, aberrant miR-155 expression has also been 
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seen in the autoimmune disorders rheumatoid arthritis, systemic lupus erythematous, 
multiple sclerosis and type 2 diabetes mellitus68–71. Zhao72 showed that miR-130A (targets 
TGFB1 and IL18 genes) was reduced in chronic active ITP compared with normal controls.    
 
1.4 Killer cell immunoglobulin-like receptors (KIR) 
 
KIRs are a family of 14 polymorphic and highly homologous genes and two 
pseudogenes, encoded on chromosome 1973 which regulate effector functions of NK cells 
and a subset of CD4+ and CD8+ T lymphocytes (that lack CD28 expression).  They were 
first identified serologically by Moretta et al.74, with functional specificity preceding 
molecular characterisation. The receptors are subdivided based on the number of 
extracellular Immunoglobulin domains (2D or 3D) and can be inhibitory or activating. 
Activating KIRs lack the immuno tyrosine inhibitory motif (ITIM) present in the intracellular 
domain of inhibitory KIRs due to a carboxy-terminal truncation of the protein, and have 
thus been named as short forms of the receptors. For example KIR3DS1 (short form) is an 
activating receptor highly related to the KIR3DL1 (long form) inhibitory receptor. Humans 
possess between four and 14 KIR receptor genes in their genome with variable numbers 
of genes inherited as a haplotype by non-homologous recombination.   
 
There are two major classes of KIR haplotypes identified as shown in figure 2. The 
A haplotype contains four genes (KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS4) in addition to 
the framework genes (KIR3DL3, KIR3DP1, KIR2DL4, KIR3DL2), representing a 
predominately inhibitory haplotype. There are many B haplotypes, containing various 
combinations of the activating KIR genes in combination with framework genes. KIR 
genotype expression varies between different immune effector cells, and determines 
whether there is phenotypic dominance of KIR-mediated inhibition over activation. The 
phenotypic expression of KIRs on NK cells is variable with regulating factors poorly 
understood. It is, however, accepted that HLA class I antigens and self-tolerance plays a 
fundamental role in NK cell “education” in the bone marrow75.   
 
 
 
 
 
 
 21 
 
Figure 2. Schematic representation of KIR haplotypes on the KIR gene locus. Reproduced with permission 
(licence number: 3746860651258)
76
. 
 
In those instances in which a KIR ligand has been identified, they are typically HLA-class I 
molecules (generally HLA-Cw but also HLA-Bw and HLA-A loci), with the same ligand 
binding both the activating KIR and its inhibitory counterpart. Both receptor and ligand 
pairs need to expressed within the individual in order of a functional interaction to occur. 
This in itself provides a challenge as HLA and KIR genes segregate differently on different 
chromosomes77. The specific HLA ligands are known for most but not all the KIRs (Table 
2)76. Unlike HLA-class I / T-cell receptor interactions, it is believed that peptides are not 
required for the HLA-class I / KIR interaction78.  
 
Table 2: KIR molecules and HLA ligands.  
KIR HLA Ligand 
KIR2DL1 HLA-C2: C*02, C*04, C*05, C*06 
KIR2DL2 HLA-C1: C*01, C*03, C*07, C*08 
HLA-C2: C*0501, C*0202, C*0401 
HLA-B: B*4601, B*7301 
KIR2DL3 HLA-C1: C*01, C*03, C*07, C*08 
HLA-C2: C*0501, C*0202 
HLA-B: B*4601, B*7301 
KIR3DL1 HLA-A and HLA-B expressing Bw4 epitope 
HLA B*08, B*27, B*57, B*58 
HLA-A: A*24, A*23, A*32 
KIR3DL2 HLA-A: A*03, A*11 
KIR3DL3 Unknown 
KIR2DL5A and B Unknown 
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KIR2DL4 HLA-G 
KIR2DS1 HLA-C2: C*02, C*04, C*05, C*06 
KIR2DS2 Unknown 
KIR2DS3 Unknown 
KIR2DS4 HLA-C: C*0501, C*1601,C*0202 
HLA-A: A*1102 
KIR2DS5 Unknown 
KIR3DS1 Unknown 
 
Genetic studies strongly implicate the presence of certain KIR genotypes, KIR 
haplotypes or KIR/HLA compound genotypes in susceptibility and outcome to diverse 
disease processes such as psoriasis/psoriatic arthritis79, rheumatoid arthritis/vasculitis, 
type I diabetes80,81, scleroderma82, multiple sclerosis83,84, pre-eclampsia85, resistance to 
HIV86,87 and HCV viral infection88, coronary artery disease, and melanoma89. In 
haematological conditions, KIR genotype associations have been seen in allogeneic and 
autologous stem cell transplantation90,91, risk for relapse in paediatric acute lymphoblastic 
leukaemia (ALL)92, chronic myeloid leukaemia (CML) and response to tyrosine kinase 
inhibitors (TKI)93,94 and incidence of plasma cell myeloma95. It is likely that there is disease 
modification by specific KIR-ligand interactions rather than by global T-cell or NK cell 
responsiveness87.  There is increasing data supporting the important role of KIR/KIR ligand 
interactions and NK cell alloreactivity in both adult and paediatric allogeneic bone marrow 
transplant influencing both graft versus disease and graft versus host effects96,97.  
 
1.5 KIRs and ITP 
 
There are very few previous studies exploring the role of KIRs in ITP. Olsson et al18 
first identified a potential role for KIRs in ITP. They investigated the role of T cells in the 
pathogenesis of ITP by performing a DNA microarray with CD3+ T-cells derived from 
patients with active ITP, ITP patients in remission and healthy controls. They 
demonstrated that genes involved in a Th1 response (interferon-γ and IL-2 receptor-β) as 
well as several cytotoxic genes (Apo-1/Fas, granzyme A, granzyme B and perforin) had 
increased expression in ITP patients compared with controls. They also showed that 
several KIR genes had increased expression in patients in remission compared with 
patients with active ITP and normal control subjects. Using flow cytometry, they  
demonstrated that increased CD3+ lymphocytes expressing KIR3DL1 and KIR3DL2  were 
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present in patients in remission compared with active ITP. These findings, in combination 
implicate CTLs in the pathogenesis of ITP. Functional studies were then performed using 
both autologous platelets and HLA-mismatched donor platelets as target cells and patient 
autologous T-cells and NK cells. They found platelet lysis occurred only when using T-cells 
as effector cells with no effect seen using NK cells. Based on this, they proposed that T-
cell mediated cytotoxicity contributes to the destruction of platelets in ITP, which is 
inhibited by up regulation of inhibitory KIRs resulting in disease remission. They did not, 
however perform ADCC based functional studies, and as such could not conclude 
anything about the role of antibody mediated CTL or NK cell responses. 
 
Our laboratory has previously performed genotyping on a cohort of patients with ITP 
and matched controls and found that the KIR2DS2/KIR2DL2 compound genotype was 
associated with adult persistent/chronic and relapsed ITP. In a similar study, reported as 
an abstract, performed in the USA, Boulad et al.98 performed KIR genotyping on a cohort 
of patients with active ITP (receiving treatment at the time) and 213 controls taken from a 
database. The ethnicity, age and genders of patients and controls was not reported. They 
found that expression of two inhibitory KIRs (KIR2DL1 and KIR2DL2) was lower in patients 
with ITP compared with controls (P<0.002) and that response to rituximab was strongly 
related to KIR expression with KIR2DL1 expression higher and KIR2DL3 expression lower 
in patients who did not respond to rituximab.  
 
In the only other study to date investigating KIRs and ITP, El-Beblawy et al.99 
performed comprehensive KIR genotyping in Egyptian children with childhood ITP. This 
study demonstrated that the KIR2DL2-/KIR2DS2- genotype was overrepresented in 
children with ITP compared with controls.  
 
2.  Hypothesis and Aims  
Hypothesis: 
That KIR genes and/or haplotypes influence the protection against and/or susceptibility 
to adult ITP. 
 
Aim: 
To assess the influence of all currently known KIR genes (with the exception of 
KIR3DL3 which is present in all haplotypes) on protection/susceptibility, to adult ITP in 
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a well-defined cohort. Results will be compared with age matched healthy volunteers in 
order to explore any disease associations with KIR genes and haplotypes. 
 
3.  Methodology  
 
3.1 Patients/Healthy Volunteers  
 
One hundred and twenty-four patients with chronic and relapsed ITP were accrued 
from multiple centres in Australia as part of a sponsored clinical trial (ML20948; 
NCT00475423). DNA was available for 95 patients consented for participation in this 
laboratory sub-analysis. Diagnosis was made according to the then current American 
Society of Hematology guidelines100. Patients were only eligible if they met stringent 
criteria. To ensure that only primary ITP was included, patients with lymphoproliferative 
disorders, multi-system autoimmune disorders, drug-induced thrombocytopenia or 
seropositivity for Human Immunodeficiency virus, Hepatitis B or C were excluded. Newly 
diagnosed ITP patients were not included. Patient characteristics including ethnicity were 
collected prospectively as part of the trial protocol. The study was approved by the 
relevant Hospital/Research Institute Ethics Committees and was performed in accordance 
with the Declaration of Helsinki. Signed informed consent was obtained from all patients in 
the study. 
  
Patients were divided into two groups. The first denoted as ‘persistent/chronic ITP’ 
was defined as ITP for more than 3 months requiring ongoing therapy to maintain a 
platelet count of ≥ 30 x 109/L. This definition is similar to the phases of disease as laid out 
by the International Working Group (IWG)5 . The second group was termed ‘relapsed ITP’. 
These were patients with an initial response as defined per IWG: namely a platelet count ≥ 
30x 109/L and at least 2-fold increase in the baseline count with absence of bleeding, 
without the requirement for ongoing therapy. Relapse in these patients was defined as a 
platelet count falling to below 30 x 109/L. It included patients with one or multiple relapses; 
for the former, relapse had to occur within 12 months of diagnosis. One hundred and six 
healthy adult volunteers, with no history of haematological or autoimmune disorders of any 
kind, served as a control cohort. Gene and polymorphism frequencies differ with ethnicity 
101, therefore for accurate interpretation of results, we ensured that our control population 
were all white. Study of healthy controls was approved by the Queensland Institute of 
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Medical Research Ethics Committee and signed informed consent was obtained from all 
participants. 
 
3.2 SSP-PCR 
DNA was previously extracted from cryopreserved peripheral blood cell pellets 
(patients) or buccal scrapes (healthy volunteers) using a commercially available DNA 
extraction kit. Analysis was performed in batches. All samples were analysed in the same 
laboratory. Of the 16 currently known KIR genes, we analysed 13 of these. KIR3DL3 was 
omitted from the analysis as it is present in 100% of the population. KIR2DL2 and 
KIR2DS2 were previously analysed by this laboratory56 so were not repeated. The 13 
remaining KIR genes were analysed by a modified version of published SSP-PCR in a set 
of 7 multiplex PCR reactions using the primers included in table 3102. Each PCR was 
performed in a reaction volume of 15 μL with a final concentration of 1.5x PCR buffer II (10 
mM Tris–HCl and 50 mM KCl), 200 μM of each dNTP, 0.6 μM of each forward and reverse 
primer (with exception of 3DP1F82 and 3DP1F83 were used at 0.3 μM final 
concentration), 2 mM of MgCl2, 0.5 unit of AmpliTaq DNA polymerase and 10 ng genomic 
DNA. PCR amplification was performed using an ABI 9700 Gene-Amp PCR System using 
the set-specific thermal cycling conditions as previously published102 and shown in table 4. 
Following amplification, 5 μL of the products (for sets 1,2,4,5,6,7) and 10 μL for set 3 were 
electrophoresed in 3% agarose gel containing ethidium bromide at low voltage for 40 
minutes. A low range ladder was also included. An example of an agarose gel of KIR 
genotyping is shown in figure 2. 
 
Four of the seven duplex PCR sets performed include primers targeting a 
framework KIR gene (sets 4 and 6) and serve as an internal positive control to confirm the 
successful PCR amplification in each of these reactions. The remaining four PCR sets 
(sets 1, 3, 5 and 7) target at least one frequently occurring KIR gene, and therefore, most 
individuals are likely positive for one of the two genes tested in each of these sets. There 
was at least one of these KIR genes positive in all our reactions in both ITP patients and 
controls. 
 
 
 
 26 
Table 3: SSP-PCR Primer combinations. 
 
 
 
 
 
Figure 3. An example of an agarose gel demonstrating the distinct bands of KIR3DS1 and KIR2DL1 in the 
set 1 PCR. 
 
 
 
Set KIR Forward primer sequence Reverse primer sequence
Amplic
on (bp)
3DS1 AGCCTGCAGGGAACAGAAG GCCTGACTGTGGTGCTCG 320
2DL1 GTTGGTCAGATGTCATGTTTGAA TCCCTGCCAGGTCTTGCG 144
3DL3 GCAATGTTGGTCAGATGTCAG GGGAGC(C/T)GACAACTCATAGGGTA 202
2DL2 AGGGGGAGGCCCATGAAT AGTGGGTCACTCGAGTTTGACC 160
2DL4 TCAGGACAAGCCCTTCTGC CACTCAGTGGGGGAGTGC 243
2DS3 TCCTATGACATGTACCATCTATCCAC GAAGCATCTGTAGGTTCCTCCT 138
2DP1 GGGGGCCTGGCCACATGA CACCGAAGAATCACATGTCCTG 693
2DS5 ACAGAGAGGGGACGTTTAACC ACAACTGATAGGGGGAGTGAGT 153
GTGTGGTAGGAGCCTTAGAAAGTG TGAAAACGGTGTTTCGGAATAC 280/399
GTACGTCACCCTCCCATGATGTA
2DS1 TTCTCCATCAGTCGCATGAA GAGGGTCACTGGGAGCTGAC 100
2DL3 CCTTCATCGCTGGTGCTG GCAGGAGACAACTTTGGATCA 814
2DL5 CATCTATCCAGGGAGGGGAG ACTCATAGGGTGAGTCATGGAG 151
7 3DL2 CCCATGAACGTAGGCTCCG GACCACACGCAGGGCAG 133
3DL1 GCAGGGAACAGAACAGCC CCGTGTACAAGATGGTATCTGTA 275
2DS4 CGGTTCAGGCAGGAGAGAAT GTTTGACCACTCGTAGGGAGC 199/221
6
8
2*
* Set 2 PCR results not included as 3DL3 was present in 100% of patients and controls and 2DS2 in this cohort 
was reported in a previous publication and not repeated. 
1
3DP1
3
4
5
 27 
Table 4: Set specific thermocycling conditions. 
PCR Set Segments Cycling conditions 
1 3,6,8 Denaturation 
Cycle 1 
Cycle 2 
Final extension 
Hold 
950C 3 min  
7 cycles of 940C for 15s, 660C for 20s, 720C for 45s 
40 cycles of 940C for 15s, 640C for 20s, 720C for 45s 
720C for 7 min 
40C  infinity 
2 4,7 Denaturation 
Cycle 1 
Cycle 2 
Final extension 
Hold 
950C 3 min  
7 cycles of 940C for 15s, 680C for 20s, 720C for 45s 
40 cycles of 940C for 15s, 660C for 20s, 720C for 45s 
720C for 7 min 
40C  infinity 
3 2 Denaturation 
Cycle 1 
Cycle 2 
Final extension 
Hold 
950C 3 min  
7 cycles of 940C for 15s, 680C for 20s, 720C for 30s 
35 cycles of 940C for 15s, 660C for 20s, 720C for 30s 
720C for 7 min 
40C  infinity 
4 1,5 Denaturation 
Cycle 1 
Cycle 2 
Final extension 
Hold 
950C 3 min  
7 cycles of 940C for 15s, 630C for 20s, 720C for 45s 
40 cycles of 940C for 15s, 610C for 20s, 720C for 45s 
720C for 7 min 
40C  infinity 
 
3.3 HLA-allotyping  
Tier 1 HLA-C allotyping was performed by ProImmune Limited (Oxford, United 
Kingdom) on 71 patient samples using a PCR-SSOP method. HLA typing was not 
performed on the control samples and 12 of the patient samples due to insufficient 
quantities of DNA available.  
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3.4 Statistics 
As a first exploratory analysis, potential associations between disease status and KIR 
genotypes were assessed via Pearson’s chi-squared test or when expected counts were 
small, Fisher’s exact test. KIR genotypes with unadjusted p-values less than 0.05 were 
considered as potential candidates to include in multivariable modelling. However, due to 
known patterns of association (i.e. genotypes in linkage disequilibrium) it was important to 
assess the relationship between genotypes in order  to ensure that genotypes that were 
co-linear (i.e. highly associated) weren't included in the same model given that including 
variables that are co-linear in a statistical model tends to produce spurious results. Co-
linearity was assessed by Pearson's chi-squared test statistic, where p-values less than 
0.05 indicated highly associated genes that were not suitable for consideration in the same 
model. This was also confirmed by LD analysis which again is designed to assess the 
level of association between genotypes. Once the candidate genes had been identified 
they were included in a binary logistic regression analysis in order to assess the effect the 
genes had in combination with each other on the binary outcome of disease status. As age 
and gender were both considered potential confounders, models were adjusted for the 
effects of age and gender regardless of their significance. As unadjusted and adjusted 
odds ratios were similar, adjusted odds ratios are reported. All analysis was performed in 
SPSS v.19. An alpha level of 0.05 was considered statistically significant. 
 
4.  Results  
4.1 Study population 
Ethnicity was available for all 95 patients, with 83 (84%) of patients identifying 
themselves as white. Due to gene and gene polymorphism frequencies differing with 
ethnicity, only the white cases were analysed. The mean age of patients was 50.5 years 
(range 18–85) with 47 (57%) females, 37 (45%) with chronic/persistent ITP and 44 (53%) 
with relapsed ITP, two people (2.4%) had primary/acute refractory ITP. In the 106 healthy 
white controls, 72 (68%) were women and mean age was 40.5 years (range 23–68 years).  
 
4.2 Genotype and allele frequencies 
We have previously shown that the distributions observed in the healthy controls for 
the KIR2DS2/2DL2 genes were in agreement with those previously reported and did not 
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deviate from the Hardy Weinberg Equilibrium (P>0.1)56,103. The distribution of KIR genes in 
both cases and healthy participants are shown in Table 5. The KIR gene frequencies did 
not differ between adult ITP patients and controls with the exception of KIR2DS3 (odds 
ratio [OR] =2.28, C.I. 1.19-4.35, P=0.012), KIR2DS5 and KIR2DL5 (OR=0.16, C.I. 0.08-
0.32, P<0.001 and OR=0.47, C.I. 0.25-0.88, P=0.017 respectively). From this we deduce 
that KIR2DS3 confers an increased risk and KIR2DS5 and KIR2DL5 confer protection 
(Figure 4). There were no significant differences noted between KIRs and the subtypes of 
ITP (chronic/persistent and relapsed ITP) so for the rest of the analysis these subtypes 
have been combined and referred to as ITP. 
 
 
A Linkage Disequilibrium (LD) plot demonstrating the LD present between the 
genes in our analysis is shown in Figure 5. From this it can be seen that our results are 
consistent with, and validated the LD data of Gourraud104. Based on our LD findings and 
the test of association in Table 6, we can further explain the significant associations 
demonstrated in Table 5. The genes that show a conferral of risk (KIR2DS2/KIR2DL2 and 
KIR2DS3) are highly positively associated. The genes that confer protection are weakly 
negatively associated with KIR2DS2 (KIR2DL5; p=0.05) or not associated at all (KIR2DS5; 
p=0.24). KIR2DL5 and KIR2DS5 are both positively associated (Chi-squared test; p-
value<0.001; data not shown), however as KIR2DL5 has a weak negative association with 
KIR2DS2/KIR2DL2 and KIR2DS3, we would expect it to correlate with another gene that 
has a protective effect regardless of any biological relationship.  As KIR2DL5 confers a 
more moderate degree of protection to adult ITP and as it is both associated with genes on 
the centromeric and telomeric region it is not an appropriate candidate for further 
modelling. However, KIR2DS5 is independently protective of ITP when adjusted for age, 
sex and KIR2DS2/2DL2 genotype (Table 7).  
 
Table 5: Distribution of genes amongst the cases and controls with accompanying 
unadjusted odds ratios.  
 
Case 
n=83 
Control 
n=106 
    
gene 
present 
(% of 
case) 
present 
(% of 
controls) 
odds 
ratio 
95% CI 
P 
value 
 
KIR2DL2 50 47 1.90 
(1.06 - 
3.41) 
0.030  
(susceptibility) (60.2%) (44.3%)     
KIR2DS2 50 45 2.05 (1.14 - 0.015  
 30 
3.68) 
(susceptibility) (60.2%) (42.5%)     
KIR3DS1 34 39 1.19 
(0.66 - 
2.15) 
0.559  
 (41.0%) (36.8%)     
KIR2DL1 81 106 NA  0.192 * 
 (97.6%) (100.0%)     
KIR2DS5 37 88 0.16 
(0.08 - 
0.32) 
<0.001  
(protective) (44.6%) (83.0%)     
KIR2DP1 82 103 2.39 
(0.24 - 
23.39) 
0.632 * 
 (98.8%) (97.2%)     
KIR2DL4 82 106 NA  0.439 * 
F/W (98.8%) (100.0%)     
KIR2DS3 31 22 2.28 
(1.19 - 
4.35) 
0.012  
(susceptibility) (37.3%) (20.8%)     
KIR3DP1 
(del) 
80 104 0.51 
(0.08 - 
3.14) 
0.655 * 
F/W (96.4%) (98.1%)     
KIR3DP1 
(undel) 
30 27 1.66 
(0.89 - 
3.10) 
0.113  
 (36.1%) (25.5%)     
KIR2DS1 31 50 0.67 
(0.37 - 
1.20) 
0.176  
 (37.3%) (47.2%)     
KIR2DL3 41 61 0.72 
(0.40 - 
1.28) 
0.265  
 (49.4%) (57.5%)     
KIR2DL5 51 82 0.47 
(0.25 - 
0.88) 
0.017  
(protective) (61.4%) (77.4%)     
KIR3DL1 78 102 0.61 
(0.16 - 
2.35) 
0.509 * 
 (94.0%) (96.2%)     
KIR2DS4 
(undel) 
32 40 1.04 
(0.57 - 
1.87) 
0.908  
 (38.6%) (37.7%)     
KIR2DS4 
(del) 
69 96 0.51 
(0.22 - 
1.22) 
0.128  
 (83.1%) (90.6%)     
KIR3DL2 83 105 NA  1.000 * 
F/W (100.0%) (99.1%)     
* indicates situations where the Fisher’s Exact Test was used to calculate the P value. In other cases, 
Pearson’s Chi-squared test was used. F/W = framework genes which are present in all haplotypes. 
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Figure 4. Odds ratio of KIR genotypes in patients versus controls 
Genetic associations of KIRs are shown as odds ratios with 95% CI. Those to the left of the central line 
confer protection over ITP and those to the right confer increased risk.  Those conferring protection are 
2DS5 (P<0.001) and 2DL5 (P=0.017) and those conferring risk include 2DS3 (P=0.012), 2DS2 (P=0.015) 
and 2DL2 (P=0.03). 
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Figure 5. Linkage disequilibrium plot demonstrating LD between KIR subtypes. 
The grey scale highlights the strength of the LD present between KIRs with the darkest grey demonstrating 
strong LD and the lighter grey, weak LD. LD estimates within the outlined regions are a result of pairwise LD 
comparisons to other KIR subtypes located in the same region. Those in the telomeric LD region (KIR2DS4, 
KIR2DS1, KIR2DS5, KIR3DS1, KIR3DL1) tend to be more highly associated with each other than to those 
on the centromeric LD region (KIR3DP1, KIR2DP1, KIR2DS3, KIR2DL2, KIR2DL3, KIR2DS2) and vice 
versa. KIR2DL4, KIR2DL1, and KIR3DL2 are not plotted, as they are present in at least 99% of subjects. 
Furthermore KIR2DL5 is not plotted as KIR2DL5A is on the telomeric region and KIR2DL5B is on the 
centromeric LD region.  
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Table 6:  Test of association between presence and absence of KIR2DS2 in both cases 
and controls. KIR2DL2 and KIR2DS3 are significantly positively associated while KIR2DL5 
is borderline significantly but negatively associated.  
 
 KIR2DS2 absent  
(total = 94) 
KIR2DS2 present  
(total = 95) 
 
KIR Gene absent present absent present p-value 
KIR2DL2 82 12 10 85 <0.001 
 (87.2%) (12.8%) (10.5%) (89.5%)  
KIR2DS3 87 7 49 46 <0.001 
 (92.6%) (7.4%) (51.6%) (48.4%)  
KIR2DL5 34 60 22 73 0.050 
 (36.2%) (63.8%) (23.2%) (76.8%)  
KIR2DS5 28 66 36 59 0.24 
 (29.8%) (70.2%) (37.9%) (61.2%)  
   
 
Table 7: Unadjusted and adjusted (for age and sex) odds ratios for a multivariable binary 
logistic regression containing KIR2DL2/KIR2DS2 and KIR2DS5. 
 
  Unadjusted  Adjusted for Sex and Age 
 
OR 95% CI 
P-
value 
OR 95% CI 
P-
value 
KIR2DL2+/KIR2DS2+ 2.37 (1.21 - 4.62) 0.01 2.24 (1.11 - 4.54) 0.025 
KIR2DS5+ 0.15 (0.07 - 0.31) <0.01 0.16 (0.07 - 0.34) <0.001 
 
 
4.3 KIR haplotypes 
Using the known defined KIR haplotypes105, study participants were allocated 
haplotypes based on whether or not they only carried the 9 genes present on the 
haplotype A (KIR3DL3–2DL3–2DP1–2DL1–3DP1–2DL4–3DL1–2DS4–3DL2). If they only 
carried these genes they were considered homozygous for the haplotype A and allocated 
the genotype A/A. Since haplotype B can contain the same genes as haplotype A, it is only 
possible to say that an individual contains at least one B haplotype. Hence, all other 
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participants were considered to carry at least one B haplotype (either BB or AB) and were 
allocated the genotype B/-. 
 
79% of patients with adult ITP were genotype B/- and 92% of healthy participants 
had this genotype. Logistic regression demonstrates that genotype B/- confers protection 
against ITP (Table 8). Given that KIR2DS5 is part of haplotype B, we then investigated 
whether the protective effect of haplotype B is due to the presence of KIR2DS5. When 
both KIR2DS5 and genotype B/- are considered in conjunction, the effect of KIR2DS5 
dominates the effect of genotype B/- rendering it non-significant (OR= 1.3, C.I. 0.4-4.27, 
P=0.66). This demonstrates that KIR2DS5 is driving the protective effect of genotype B/- 
more so than the other genes in genotype B/-.  
 
Table 8: Unadjusted and adjusted (for age and sex) odds ratios for a binary logistic 
regression containing haplotype B/- . 
 
  Unadjusted  Adjusted for Sex and Age 
 
OR 95% CI 
P-
value 
OR 95% CI 
P-
value 
Haplotype B/- 0.37 (0.15 - 0.92) 0.033 0.31 (0.12 - 0.84) 0.021 
 
 
4.4 Compound Genotypes 
As previously shown, KIR2DL2/2DS2 is significantly related to increased risk of 
developing ITP; more so than just KIR2DL2 and KIR2DS2 alone56. Including 
KIR2DL2/2DS2 in our analysis, omits the need to include KIR2DS3 (as it exhibits strong 
LD with KIR2DL2 and KIR2DS2). Table 9 shows that there is increased risk of ITP in the 
KIR2DS2/2DL2 positive population that are KIR2DS5 negative (adjusted for age/gender, 
OR=4.48, C.I. 1.17–17.15, P=0.029), and also that there is a decreased risk of ITP 
(protective) in those that are KIR2DS5 positive and KIR2DS2/2DL2 negative. Interestingly, 
in those positive for KIR2DS2/2DL2 and KIR2DS5 both the independent risk and 
protective effects appear to be ameliorated (P=NS).  
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Table 9: Confidence intervals for the combinations of 2DS2/2DL2 compound genotype 
and 2DS5 demonstrates that the combination of 2DS2/2DL2 and 2DS5 largely negates the 
risk of 2DS2/2DL2 and the protective benefit of 2DS5 (adjusted for age and sex).  
  Unadjusted  Adjusted for Sex and Age 
 OR 95% CI 
P-
value OR 95% CI 
P-
value 
2DS2/DL2-
/2DS5- 1    1   
2DS2/2DL2+ / 
2DS5- 
5.12 (1.42 - 18.41) 0.012 4.48 
(1.17 - 
17.15) 
0.029 
2DS2/2DL2-/ 
2DS5+ 
0.24 (0.09 - 0.61) 0.003 0.24 (0.09 - 0.64) 0.004 
2DS2/2DL2+ / 
2DS5+ 
0.41 (0.16 - 1.03) 0.058 0.40 (0.15 - 1.08) 0.069 
 
 
4.5 HLA-C allotypes 
The ligand for KIR2DS5 is unknown. However, as the HLA-C2 allotype has been 
associated with protection against ankylosing spondylitis and acute rejection of renal 
allograft 106, we investigated the distribution of HLA-C allotypes in our ITP cohort. HLA-C 
allotypes were allocated into relevant KIR ligand groups, C1 and C2, based on the table 
published by Khakoo et al.107.  In the patient samples tested, we found that 44% had the 
genotype C1C1, 8% C2C2 and 48% C1C2. This distribution of allotypes was not 
significantly different (p=0.35) to the “healthy” population (i.e. those with a resolved 
hepatitis C infection) reported in Khakoo et al. 107. As such there is no evidence to suggest 
there is an interaction between ITP and HLA-C allotype. Furthermore there was no 
association found between HLA-C type and KIR2DS5 positivity in patients with ITP 
(P=0.77). 
 
5.  Discussion  
In this study, I have performed the first prospective case-control genetic association 
study comparing the comprehensive KIR repertoire with the presence of adult ITP. 
Analysis was restricted to a cohort of well-defined chronic/persistent and relapsed ITP 
patients. KIR genotype was compared with healthy control participants. Data were 
adjusted for the effects of age and sex. I identified a number of significant associations, 
including notably the novel finding of the protective influence of the presence of KIR2DS5. 
Logistic regression analysis showed the protective effect conferred by KIR2DS5 dominates 
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the effect of the B-haplotype. I also demonstrated certain KIR genes associated with 
increased risk of the development of ITP. Previously we found an association of the 
compound genotype KIR2DS2/2DL2 with ITP and extended to this in the current study by 
showing that KIR2DS3 also confers increased risk56. It has previously been described by 
Middleton108 that KIR2DS3 can map to both centromeric and telomeric regions of the KIR 
gene cluster which could in theory affect the interpretation of its LD relationship with 
KIR2DS2 and KIR2DL2. Although I did not determine the allelic position of the KIR2DS3 
gene in our patient and control groups, I did determine through LD analysis that KIR2DS3 
is in strong LD with KIR2DS2 and KIR2DS3 and the increased risk seen with this was not 
independent. 
 
For comparison of KIR frequencies I tested 106 white volunteers. Those with a 
history of autoimmunity or cancer were specifically excluded. The frequency of haplotype 
B in our white control population (92%) was higher than that in the published literature of 
white populations (mean 75%)107. The majority of published KIR frequency studies are 
from European populations, and there is no frequency data of KIRs in white Australians 
available. This highlights the importance of ethnic variability when studying KIR 
associations. 
 
Although KIR disease association studies have been carried out in a variety of 
autoimmune, infectious and malignant diseases, the protective effect of KIR2DS5 has 
been shown in only a few other diseases (ankylosing spondylitis, acute rejection of renal 
allograft)106. Howe and colleagues also showed a non-significant trend with KIR2DS5 
being underrepresented in patients with the bone marrow failure syndromes Aplastic 
Anaemia and Paroxysmal Nocturnal Haemoglobinuria109. KIR2DS5 is also associated with 
leukemia free survival after HLA identical hematopoietic stem cell transplantation110. The 
mechanism for the protective effect of the activating KIR2DS5 seen in ITP is not known, 
but may involve altering the balance of inhibitory and activating KIRs to favour induction of 
immune tolerance and the subsequent reduced risk of developing autoimmunity106. MHC 
class I (particularly HLA-C) molecules are known to be ligands for specific KIRs 111. 
However, no ligand has been identified for KIR2DS5. It has been suggested that there is 
an association between HLA-C2 and protection against ankylosing spondylitis106, but no 
evidence of an interaction between KIR2DS5 and any HLA class I molecule has be 
demonstrated. It may be that associations of KIR2DS5 and ITP are due to LD and actually 
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reflect other KIR/HLA interactions106. I have, however demonstrated that in adult ITP, the 
protective effect of KIR2DS5 is independent and not associated with LD or HLA-C allotype. 
 
This study adds to the accumulating evidence that KIRS contributes to the 
pathogenesis of adult ITP. A pathogenetic model for the association of KIR genotype with 
ITP is unclear. KIR proteins are expressed in both NK and effector T-cells. The activation 
of these cells is controlled by a balance between a genetically determined repertoire of 
activating and inhibitory KIRs112. It has been demonstrated that in both cell types, 
activating KIRs are involved in direct cell-mediated cytotoxicity although through different 
mechanisms.  Activating KIRs in NK cells results in the direct activation of the cell, 
however in cytotoxic CD8+ T-cells, activating KIRS act as co-stimulatory receptors that 
boost the response to T-cell receptor (TCR) cross linking and ultimate cell activation113.  
 
In the ground-breaking study by Olsson et al, (discussed above), autologous T-cells 
from patients with active chronic ITP (but not from those with ITP in remission) were 
shown to mediate platelet destruction18. By contrast, autologous NK cells were incapable 
of inducing direct platelet cytolysis. Moreover, the inhibitory KIR2DL3, KIR3DL2 and 
KIR3DL1 were up-regulated in the T-cells of patients with ITP in remission relative to those 
with active disease18. Olsson selected the KIRs to be investigated by using CD3+ T-cell 
microarray to investigate for preferential gene expression in 8 patients with active ITP, 6 
patients with ITP in remission and 6 healthy controls. Although this technique did not 
identify KIR2DS5 as a potential protective candidate, the numbers were small and 
comprehensive KIR genotyping not performed. Similarly, my study was not designed to 
measure levels of KIR gene or protein expression within T- or NK-cells. Along these lines, 
it remains to be definitively established whether KIR2DL2/KIR2DS2 and KIR2DS5 genes 
influence T-cell-mediated platelet cytotoxicity. Alternatively, they may influence indirect 
destruction of autoantibody bound platelets by NK-cells. Notably, NK-cell mediated 
destruction of platelets by ADCC was not tested in the study of Olsson et al. Although it is 
known that in-vitro KIR manipulation can modulate ADCC112, the role of NK-cell-mediated 
ADCC in ITP has yet to be determined.  
 
My thesis provides a rational platform for future studies to confirm and further 
elucidate the functional effect of KIRS, in particular KIR2DS5 in ITP. These should include 
comprehensive KIR genotyping in other ITP cohorts, in particular paediatric ITP, 
secondary ITP and ITP in different ethnicities.  Given the highly variable responses to 
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rituximab seen in ITP, functional studies looking at the impact of KIRs on conventional 
rituximab dosing and the effect of other independent influencing factors such as FCGR 
receptor polymorphisms are warranted.  Functional assays that test the ability to enhance 
rituximab anti-ITP responses by blocking inhibitory KIRs would also be of interest. 
Lirilumab is a first-in-class mAb that prevents inhibitory Killer-cell immunoglobulin-like 
receptors (KIRs) on NK-cells engaging with their ligand. Specifically, it blocks HLA-C1/C2 
engagement to the 3 main inhibitory KIRs 2DL-1 (universally expressed) and KIR2DL-2/-3. 
My data indicates that these are present in 100% (-1), -44.3% (-2), 57.5% (-3) of healthy 
Australian Caucasians, values which are consistent with non-Australian data. Along these 
lines, identification of the HLA ligand to KIR2DS5 will not only assist in establishing the 
mechanistic basis for my observations but may provide a potential target for therapeutic 
manipulation. 
 
In summary, in a comparison of relevant healthy control volunteers and a tightly 
defined cohort of adult ITP patients, the presence of KIR2DS5 was independently 
associated with protection against ITP. By multivariable binary logistic regression to adjust 
for age, sex and the effects of other KIR genes, the compound genotype of 
KIR2DS2/2DL2 with KIR2DS5 abrogated the risk of KIR2DS2/2DL2 and the protective 
benefit of 2DS5. These findings shed new light on the immunobiology of adult 
persistent/chronic and relapsed ITP.  
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ABSTRACT 
Immune thrombocytopenia (ITP) is an autoimmune disorder of unknown aetiology, 
characterised by an isolated low platelet count in the absence of other identifiable causes. 
Genes influencing activation of the immune system have been identified as influencing 
predisposition. Killer cell immunoglobulin-like receptors (KIR) control T-cell and Natural 
Killer cell function via inhibitory and activating signalling pathways. The inhibitory 
KIR2DL3, KIR3DL2 and KIR3DL1 are up-regulated in the T-cells of patients with ITP in 
remission relative to those with active disease, and an association of KIR2DS2/KIR2DL2 
with ITP has also been reported. No comprehensive KIR analysis in ITP has been 
reported. We performed genotyping of all currently known KIR genes using sequence 
specific primer polymerase chain reaction (SSP-PCR) on a cohort of 83 adult patients with 
ITP (chronic/persistent or relapsed primary ITP identified by defined criteria) and 106 age 
matched healthy white volunteers. Non-white patients were not included in the analysis. 
There was an over-representation of KIR2DS3 (known to be in linkage disequilibrium with 
KIR2DS2/2DL2) and under-representation of KIR2DS5 (also protective against other 
immune mediated disorders) in adult ITP (odds ratio 0.16, C.I. 0.08-0.32, P<0.001). By 
multivariable binary logistic regression to adjust for age, sex and the effects of other KIR 
genes, the presence of KIR2DS2/2DL2 with KIR2DS5 abrogated the risk of 
KIR2DS2/2DL2 and the protective benefit of KIR2DS5. Further studies are required to 
establish the mechanistic basis for these observations and their potential impact on ITP 
therapy.  
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INTRODUCTION 
Immune thrombocytopenia (ITP) is a disorder characterised by isolated 
thrombocytopenia due to autoimmune mediated platelet destruction occurring in both 
paediatric and adult populations. Paediatric ITP is generally precipitated by an acute 
infection and is usually self-limiting. In contrast, in adult ITP, many patients relapse or 
progress to chronic ITP indicating a distinct pathophysiology. Pathogenesis of ITP is a 
complex multifactorial process involving an immune mediated peripheral destruction of 
platelets and insufficient bone marrow production. Further understanding of the 
immunobiology of adult chronic and relapsed ITP is required in order to develop novel 
targeted therapies. 
There are a number of polymorphisms associated with genetic predisposition to 
adult ITP (1). Our laboratory has demonstrated that the FCgamma receptor polymorphism 
FCGR3a-V158 was overrepresented in adult patients with ITP compared with healthy 
white volunteers. This study also demonstrated that the presence of Killer cell 
immunoglobulin-like immunoglobulin receptor (KIR) genes KIR2DS2/KIR2DL2 was 
associated with increased susceptibility to adult ITP independently of FCGR3a-158 
polymorphisms (2). Olsson et al. demonstrated that the inhibiting KIR2DL3, KIR3DL2 and 
KIR3DL1 are known to be up-regulated in the T-cells of patients with ITP in remission 
relative to those with active disease (3). 
KIRs are a family of polymorphic and highly homologous genes that regulate 
effector functions of NK cells and a subset of CD4+ and CD8+ T lymphocytes (that lack 
CD28 expression). They are subdivided based on the number of extracellular 
Immunoglobulin domains (2D or 3D) and can be inhibitory or activating. Activating KIRs 
lack the immuno tyrosine inhibitory motif (ITIM) present in the intracellular domain of 
inhibitory KIRs due to a carboxy-terminal truncation of the protein, and have thus been 
named as short forms of the receptors. KIR genotype expression varies between different 
immune effector cells, and determines whether there is phenotypic dominance of KIR-
mediated inhibition over activation. Genetic studies strongly implicate the presence of 
certain KIR genotypes, KIR haplotypes or KIR/HLA compound genotypes in susceptibility 
and outcome to diverse disease processes such as psoriasis/psoriatic arthritis (4), 
rheumatoid arthritis/vasculitis, type I diabetes (5,6), scleroderma (7), multiple sclerosis 
(8,9), pre-eclampsia (10), resistance to HIV (11,12)and HCV viral infection (13), coronary 
artery disease, and melanoma (14). Rituximab (an anti-CD20 monoclonal antibody) is an 
established treatment of adult ITP (15). The distribution of KIR genes in adult ITP may 
influence antibody mediated cellular cytotoxicity (16) and hence the response to antibody-
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mediated therapies. Prospective studies are required to establish their impact on rituximab 
response in adult chronic/persistent and relapsed ITP. 
To our knowledge, no prior comprehensive KIR gene association study has been 
performed in adult ITP. Therefore, we performed this laboratory sub study on samples 
obtained from a large prospective study to assess the influence of all currently known KIR 
genes (with the exception of KIR3DL3 which is present in all haplotypes) on susceptibility 
in a well-defined cohort of chronic and relapsed adult ITP and age matched healthy 
volunteers in order to explore any disease associations with the presence or absence of 
KIR genes and haplotypes. 
 
METHODS 
Patients and healthy volunteer recruitment 
One hundred and twenty-four patients with chronic and relapsed ITP were accrued 
from multiple centres in Australia as part of a sponsored clinical trial (ML20948; 
NCT00475423). DNA was available for 95 patients that consented for participation in this 
laboratory sub-analysis. Diagnosis was made according to the then current American 
Society of Hematology guidelines (17). Patients were only eligible if they met stringent 
criteria. To ensure that only primary ITP was included, patients with lymphoproliferative 
disorders, multi-system autoimmune disorders, drug-induced thrombocytopenia or 
seropositivity for Human Immunodeficiency virus, Hepatitis B or C were excluded. Newly 
diagnosed ITP patients were not included. Patient characteristics including ethnicity were 
collected prospectively as part of the trial protocol. The study was approved by the 
relevant Hospital/Research Institute Ethics Committees and was performed in accordance 
with the Declaration of Helsinki. Signed informed consent was obtained from all patients in 
the study. 
 Patients were divided into two groups. The first denoted as ‘persistent/chronic ITP’ 
was defined as ITP for more than 3 months requiring ongoing therapy to maintain a 
platelet count of ≥ 30 x 109/L. This definition is similar to the phases of disease as laid out 
by the International Working Group (IWG) (18) . The second group was termed ‘relapsed 
ITP’. These were patients with an initial response as defined per IWG: namely a platelet 
count ≥ 30x 109/L and at least 2-fold increase in the baseline count with absence of 
bleeding, without the requirement for ongoing therapy. Relapse in these patients was 
defined as a platelet count falling to below 30 x 109/L. It included patients with one or 
multiple relapses; for the former, relapse had to occur within 12 months of diagnosis. One 
hundred and six healthy adult volunteers, with no history of haematological or autoimmune 
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disorders of any kind, served as a control cohort. Gene and polymorphism frequencies 
differ with ethnicity (19), therefore for accurate interpretation of results, we ensured that 
our control population were all white. Study of healthy controls was approved by the 
Queensland Institute of Medical Research Ethics Committee and signed informed consent 
was obtained from all participants. 
 
Sequence Specific Primer directed Polymerase chain reaction (SSP-PCR)  
DNA was extracted from cryopreserved peripheral blood cell pellets (patients) or 
buccal scrapes (healthy volunteers) using standard procedures and analysis performed in 
batches. All samples were analysed in the same laboratory. Of the 16 currently known KIR 
genes, we analysed 13 of these. KIR3DL3 was omitted from the analysis as it is present in 
100% of the population. KIR2DL2 and KIR2DS2 were previously analysed by this 
laboratory (2) so were not repeated. The 13 remaining KIR genes were analysed by a 
modified version of published SSP-PCR in a set of 7 multiplex PCR reactions using the 
same primers (20)
concentration of 1.5x PCR buffer II (10 mM Tris–
F82 and 
DNA polymerase and 10 ng genomic DNA. PCR amplification was performed using an ABI 
9700 Gene-Amp PCR System using the set-specific thermal cycling conditions as 
previously published (20)
et 3 were electrophoresed in 3% agarose gel containing 
ethidium bromide at low voltage for 40 minutes. A low range ladder was also included. 
Four of the seven duplex PCR sets performed include primers targeting a 
framework KIR gene (sets 2, 4 and 6) and serve as an internal positive control to confirm 
the successful PCR amplification in each of these reactions. The remaining four PCR sets 
(sets 1, 3, 5 and 7) target at least one frequently occurring KIR gene, and therefore, most 
individuals are likely positive for one of the two genes tested in each of these sets. There 
was at least one of these KIR genes positive in all our reactions in both ITP patients and 
controls. 
 
Human Leukocyte Antigen (HLA) Allotyping 
Tier 1 HLA-C allotyping was performed by ProImmune Limited (Oxford, United 
Kingdom) on 71 patient samples using a PCR-SSOP method. HLA typing was not 
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performed on the control samples and 12 of the patient samples due to insufficient 
quantities of DNA available.  
 
Statistical analysis 
To identify potential associations between disease status and KIR genotypes, 
Pearson’s chi-squared test was performed. Alternatively, when expected counts were 
small, Fisher’s exact test was used. Binary logistic regression was used to assess the 
effect genes had in combination. Genes in linkage disequilibrium were not included in the 
same model. In addition, effect sizes were adjusted for both age and gender. Unadjusted 
and adjusted odds ratios are reported. All analysis was performed in SPSS v.19. An alpha 
level of 0.05 was considered statistically significant. 
  
RESULTS 
Study population 
Ethnicity was available for all 95 patients, with 83 (84%) of patients identifying 
themselves as white. Due to gene and gene polymorphism frequencies differing with 
ethnicity, only the white cases were analysed. The mean age of patients was 50.5 years 
(range 18–85) with 47 (57%) females, 37 (45%) with chronic/persistent ITP and 44 (53%) 
with relapsed ITP, two people (2.4%) had primary/acute refractory ITP. In the 106 healthy 
white controls, 72 (68%) were women and mean age was 40.5 years (range 23–68 years).  
 
Genotype and allele frequencies. 
 We have previously shown that the distributions observed in the healthy controls for 
the KIR2DS2/2DL2 genes were in agreement with those previously reported and did not 
deviate from the Hardy Weinberg Equilibrium (P>0.1)(2,21). The distribution of KIR genes 
in both cases and healthy participants are shown in Table 1. The KIR gene frequencies did 
not differ between adult ITP patients and controls with the exception of KIR2DS3 (odds 
ratio [OR] =2.28, C.I. 1.19-4.35, P=0.012), KIR2DS5 and KIR2DL5 (OR=0.16, C.I. 0.08-
0.32, P<0.001 and OR=0.47, C.I. 0.25-0.88, P=0.017 respectively). From this we deduce 
that KIR2DS3 confers an increased risk and KIR2DS5 and KIR2DL5 confer protection 
(Figure 1). There were no significant differences noted between KIRs and the subtypes of 
ITP (chronic/persistent and relapsed ITP) so for the rest of the analysis these subtypes 
have been combined and referred to as ITP. 
A Linkage Disequilibrium (LD) plot demonstrating the LD present between the 
genes in our analysis is shown in Figure 2. From this it can be seen that our results are 
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consistent with, and validated the LD data of Gourraud (22). Based on our LD findings and 
the test of association in Table 2, we can further explain the significant associations 
demonstrated in Table 1. The genes that show a conferral of risk (KIR2DS2/KIR2DL2 and 
KIR2DS3) are highly positively associated. The genes that confer protection are weakly 
negatively associated with KIR2DS2 (KIR2DL5; p=0.05) or not associated at all (KIR2DS5; 
p=0.24). KIR2DL5 and KIR2DS5 are both positively associated (Chi-squared test; p-
value<0.001; data not shown), however as KIR2DL5 has a weak negative association with 
KIR2DS2/KIR2DL2 and KIR2DS3, we would expect it to correlate with another gene that 
has a protective effect regardless of any biological relationship.  As KIR2DL5 confers a 
more moderate degree of protection to adult ITP and as it is both associated with genes on 
the centromeric and telomeric region it is not an appropriate candidate for further 
modelling. However, KIR2DS5 is independently protective of ITP when adjusted for age, 
sex and KIR2DS2/2DL2 genotype (OR=0.16, C.I. 0.07-0.34, P<0.001). 
 
KIR Haplotypes 
Using the known defined KIR haplotypes (23), study participants were allocated 
haplotypes based on whether or not they only carried the 9 genes present on the 
haplotype A (KIR3DL3–2DL3–2DP1–2DL1–3DP1–2DL4–3DL1–2DS4–3DL2). If they only 
carried these genes they were considered homozygous for the haplotype A and allocated 
the genotype A/A. Since haplotype B can contain the same genes as haplotype A, it is only 
possible to say that an individual contains at least one B haplotype. Hence, all other 
participants were considered to carry at least one B haplotype (either BB or AB) and were 
allocated the genotype B/-. 
79% of patients with adult ITP were genotype B/- and 92% of healthy participants 
had this genotype. Logistic regression demonstrates that genotype B/- confers protection 
against ITP (adjusted for age/gender, OR=0.31, C.I. 0.12-0.84, P=0.021). Given that 
KIR2DS5 is part of haplotype B, we then investigated whether the protective effect of 
haplotype B is due to the presence of KIR2DS5. When both KIR2DS5 and genotype B/- 
are considered in conjunction, the effect of KIR2DS5 dominates the effect of genotype B/- 
rendering it non-significant (OR= 1.3, C.I. 0.4-4.27, P=0.66). This demonstrates that 
KIR2DS5 is driving the protective effect of genotype B/- more so than the other genes in 
genotype B/-.  
 
Compound genotypes 
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As previously shown, KIR2DL2/2DS2 is significantly related to increased risk of 
developing ITP; more so than just KIR2DL2 and KIR2DS2 alone (2). Including 
KIR2DL2/2DS2 in our analysis, omits the need to include KIR2DS3 (as it exhibits strong 
LD with KIR2DL2 and KIR2DS2). Table 3 shows that there is increased risk of ITP in the 
KIR2DS2/2DL2 positive population that are KIR2DS5 negative (adjusted for age/gender, 
OR=4.48, C.I. 1.17–17.15, P=0.029), and also that there is a decreased risk of ITP 
(protective) in those that are KIR2DS5 positive and KIR2DS2/2DL2 negative. Interestingly, 
in those positive for KIR2DS2/2DL2 and KIR2DS5 both the independent risk and 
protective effects appear to be ameliorated (P=NS).  
 
HLA-C Allotypes 
 The ligand for KIR2DS5 is unknown. However, as the HLA-C2 allotype has been 
associated with protection against ankylosing spondylitis and acute rejection of renal 
allograft (24), we investigated the distribution of HLA-C allotypes in our ITP cohort. HLA-C 
allotypes were allocated into relevant KIR ligand groups, C1 and C2, based on the table 
published by Khakoo et al. (25).  In the patient samples tested, we found that 44% had the 
genotype C1C1, 8% C2C2 and 48% C1C2. This distribution of allotypes was not 
significantly different (p=0.35) to the “healthy” population (i.e. those with a resolved 
hepatitis C infection) reported in Khakoo et al. (25). As such there is no evidence to 
suggest there is an interaction between ITP and HLA-C allotype. Furthermore there was 
no association found between HLA-C type and KIR2DS5 positivity in patients with ITP 
(P=0.77). 
  
DISCUSSION 
In this study, we performed the first prospective case-control genetic association 
study comparing the comprehensive KIR repertoire with the presence of adult ITP. 
Analysis was restricted to a cohort of well-defined chronic/persistent and relapsed ITP 
patients. KIR genotype was compared with healthy control participants. Data were 
adjusted for the effects of age and sex. We identified a number of significant associations, 
including notably the novel finding of the protective influence of the presence of KIR2DS5. 
Logistic regression analysis showed the protective effect conferred by KIR2DS5 dominates 
the effect of the B-haplotype. We also demonstrated certain KIR genes associated with 
increased risk of the development of ITP. Previously we found an association of the 
compound genotype KIR2DS2/2DL2 with ITP and extended to this in the current study by 
showing that KIR2DS3 also confers increased risk (2). It has previously been described by 
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Middleton (26) that KIR2DS3 can map to both centromeric and telomeric regions of the 
KIR gene cluster which could in theory affect the interpretation of its LD relationship with 
KIR2DS2 and KIR2DL2. Although we did not determine the allelic position of the KIR2DS3 
gene in our patient and control groups, we did determine through LD analysis that 
KIR2DS3 is in strong LD with KIR2DS2 and KIR2DS3 and the increased risk seen with this 
was not independent. 
For comparison of KIR frequencies we tested 106 white volunteers. Those with a 
history of autoimmunity or cancer were specifically excluded. The frequency of haplotype 
B in our white control population (92%) was higher than that in the published literature of 
white populations (mean 75%) (25). The majority of published KIR frequency studies are 
from European populations, and there is no frequency data of KIRs in white Australians 
available. This highlights the importance of ethnic variability when studying KIR 
associations. 
Although KIR disease association studies have been carried out in a variety of 
autoimmune, infectious and malignant diseases, the protective effect of KIR2DS5 has 
been shown in only a few other diseases (ankylosing spondylitis, acute rejection of renal 
allograft) (24). Howe and colleagues also showed a non-significant trend with KIR2DS5 
being underrepresented in patients with the bone marrow failure syndromes Aplastic 
Anaemia and Paroxysmal Nocturnal Haemoglobinuria (27). KIR2DS5 is also associated 
with leukemia free survival after HLA identical hematopoietic stem cell transplantation (28). 
The mechanism for the protective effect of the activating KIR2DS5 seen in ITP is not 
known, but may involve altering the balance of inhibitory and activating KIRs to favour 
induction of immune tolerance and the subsequent reduced risk of developing 
autoimmunity (24). MHC class I (particularly HLA-C) molecules are known to be ligands for 
specific KIRs (29). However, no ligand has been identified for KIR2DS5. It has been 
suggested that there is an association between HLA-C2 and protection against ankylosing 
spondylitis (24), but no evidence of an interaction between KIR2DS5 and any HLA class I 
molecule has be demonstrated. It may be that associations of KIR2DS5 and ITP are due 
to LD and actually reflect other KIR/HLA interactions (24). We have, however 
demonstrated that in adult ITP, the protective effect of KIR2DS5 is independent and not 
associated with LD or HLA-C allotype. 
This study adds to the accumulating evidence that KIRS contributes to the 
pathogenesis of adult ITP. A pathogenetic model for the association of KIR genotype with 
ITP is unclear. KIR proteins are expressed in both NK and effector T-cells. The activation 
of these cells is controlled by a balance between a genetically determined repertoire of 
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activating and inhibitory KIRs (30). It has been demonstrated that in both cell types, 
activating KIRs are involved in direct cell-mediated cytotoxicity although through different 
mechanisms.  Activating KIRs in NK cells results in the direct activation of the cell, 
however in cytotoxic CD8+ T-cells, activating KIRS act as co-stimulatory receptors that 
boost the response to T-cell receptor (TCR) cross linking and ultimate cell activation (31).  
In a ground-breaking study by Olsson et al, autologous T-cells from patients with 
active chronic ITP (but not from those with ITP in remission) were shown to mediate 
platelet destruction (3). By contrast, autologous NK cells were incapable of inducing direct 
platelet cytolysis. Moreover, the inhibitory KIR2DL3, KIR3DL2 and KIR3DL1 were up-
regulated in the T-cells of patients with ITP in remission relative to those with active 
disease (3). Olsson selected the KIRs to be investigated by using CD3+ T-cell microarray 
to investigate for preferential gene expression in 8 patients with active ITP, 6 patients with 
ITP in remission and 6 healthy controls. Although this technique did not identify KIR2DS5 
as a potential protective candidate, the numbers were small and comprehensive KIR 
genotyping not performed. Similarly, our study was not designed to measure levels of 
gene expression within T- or NK-cells. Along these lines, it remains to be definitively 
established whether KIR2DL2/KIR2DS2 and KIR2DS5 genes influence T-cell-mediated 
platelet cytotoxicity. Alternatively, they may influence indirect destruction of autoantibody 
bound platelets by NK-cells. Although it is known that in-vitro KIR manipulation can 
modulate ADCC (32), the role of NK-cell-mediated ADCC in ITP has yet to be determined. 
In summary, in a comparison of relevant healthy control volunteers and a tightly 
defined cohort of adult ITP patients, the presence of KIR2DS5 was independently 
associated with protection against ITP. By multivariable binary logistic regression to adjust 
for age, sex and the effects of other KIR genes, the compound genotype of 
KIR2DS2/2DL2 with KIR2DS5 abrogated the risk of KIR2DS2/2DL2 and the protective 
benefit of 2DS5. These findings shed new light on the immunobiology of adult 
persistent/chronic and relapsed ITP. Identification of the HLA ligand to KIR2DS5 will assist 
in establishing the mechanistic basis for these observations. Further studies are required 
to determine the impact of KIRS on ITP therapy. 
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Table 1: Distribution of genes amongst the cases and controls with accompanying 
unadjusted odds ratios.  
 
Case 
n=83 
Control 
n=106 
    
gene 
present 
(% of 
case) 
present 
(% of 
controls) 
odds 
ratio 
95% CI P value  
KIR2DL2 50 47 1.90 
(1.06 - 
3.41) 
0.030  
(susceptibility) (60.2%) (44.3%)     
KIR2DS2 50 45 2.05 
(1.14 - 
3.68) 
0.015  
(susceptibility) (60.2%) (42.5%)     
KIR3DS1 34 39 1.19 
(0.66 - 
2.15) 
0.559  
 (41.0%) (36.8%)     
KIR2DL1* 81 106 NA  0.192  
 (97.6%) (100.0%)     
KIR2DS5 37 88 0.16 
(0.08 - 
0.32) 
<0.001  
(protective) (44.6%) (83.0%)     
KIR2DP1* 82 103 2.39 
(0.24 - 
23.39) 
0.632  
 (98.8%) (97.2%)     
KIR2DL4 82 106 NA  0.439  
F/W (98.8%) (100.0%)     
KIR2DS3 31 22 2.28 
(1.19 - 
4.35) 
0.012  
(susceptibility) (37.3%) (20.8%)     
KIR3DP1 
(del)*# 
80 104 0.51 
(0.08 - 
3.14) 
0.655  
F/W (96.4%) (98.1%)     
KIR3DP1 
(undel)# 
30 27 1.66 
(0.89 - 
3.10) 
0.113  
 (36.1%) (25.5%)     
KIR2DS1 31 50 0.67 
(0.37 - 
1.20) 
0.176  
 (37.3%) (47.2%)     
KIR2DL3 41 61 0.72 
(0.40 - 
1.28) 
0.265  
 (49.4%) (57.5%)     
KIR2DL5 51 82 0.47 
(0.25 - 
0.88) 
0.017  
(protective) (61.4%) (77.4%)     
KIR3DL1* 78 102 0.61 
(0.16 - 
2.35) 
0.509  
 (94.0%) (96.2%)     
KIR2DS4 
(undel) 
32 40 1.04 
(0.57 - 
1.87) 
0.908  
 (38.6%) (37.7%)     
KIR2DS4 69 96 0.51 (0.22 - 0.128  
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(del) 1.22) 
 (83.1%) (90.6%)     
KIR3DL2* 83 105 NA  1.000  
F/W (100.0%) (99.1%)     
* indicates situations where the Fisher’s Exact Test was used to calculate the P value. In 
other cases, Pearson’s Chi-squared test was used. F/W = Framework genes which are 
present in virtually all haplotypes. # Three of the six known KIR3DP1 alleles have deletions 
of exon 2 and part of its flanking introns 1 and 2 compared with the remaining three alleles. 
The genotyping method used was able to distinguish between the deleted and undeleted 
forms. KIR3DP1 in either the deleted or undeleted form is present in 100% of cases and 
controls. 
 
 
 
Table 2:  Test of association between presence and absence of KIR2DS2 in both cases 
and controls. KIR2DL2 and KIR2DS3 are significantly positively associated while KIR2DL5 
is borderline significantly but negatively associated.  
 
 KIR2DS2 absent  
(total = 94) 
KIR2DS2 present  
(total = 95) 
 
KIR Gene absent present absent present p-value 
KIR2DL2 82 12 10 85 <0.001 
 (87.2%) (12.8%) (10.5%) (89.5%)  
KIR2DS3 87 7 49 46 <0.001 
 (92.6%) (7.4%) (51.6%) (48.4%)  
KIR2DL5 34 60 22 73 0.050 
 (36.2%) (63.8%) (23.2%) (76.8%)  
KIR2DS5 28 66 36 59 0.24 
 (29.8%) (70.2%) (37.9%) (61.2%)  
   
 
 
 
 
Table 3: Confidence intervals for the combinations of KIR2DS2/2DL2 compound genotype 
and KIR2DS5 demonstrates that the combination of KIR2DS2/2DL2 and KIR2DS5 largely 
negates the risk of KIR2DS2/2DL2 and the protective benefit of KIR2DS5 (adjusted for age 
and sex).  
  Adjusted for Sex and Age 
 OR 95% CI 
P-
value 
KIR2DS2/DL2-
/2DS5- 1   
KIR2DS2/2DL2+ 
/ 2DS5- 
4.48 
(1.17 - 
17.15) 
0.029 
KIR2DS2/2DL2-
/ 2DS5+ 
0.24 (0.09 - 0.64) 0.004 
KIR2DS2/2DL2+ 
/ 2DS5+ 
0.40 (0.15 - 1.08) 0.069 
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Figure 1. Odds ratio of KIR genotypes in patients versus controls 
Genetic associations of KIRs are shown as odds ratios with 95% CI. Those to the left of 
the central line confer protection over ITP and those to the right confer increased risk.  
Those conferring protection are KIR2DS5 (P<0.001) and KIR2DL5 (P=0.017) and those 
conferring risk include KIR2DS3 (P=0.012), KIR2DS2 (P=0.015) and KIR2DL2 (P=0.03). 
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Figure 2. Linkage disequilibrium plot demonstrating LD between KIR subtypes. 
The grey scale highlights the strength of the LD present between KIRs with the darkest 
grey demonstrating strong LD and the lighter grey, weak LD. LD estimates within the 
outlined regions are a result of pairwise LD comparisons to other KIR subtypes located in 
the same region. Those in the telomeric LD region (KIR2DS4, KIR2DS1, KIR2DS5, 
KIR3DS1, KIR3DL1) tend to be more highly associated with each other than to those on 
the centromeric LD region (KIR3DP1, KIR2DP1, KIR2DS3, KIR2DL2, KIR2DL3, KIR2DS2) 
and vice versa. KIR2DL4, KIR2DL1, and KIR3DL2 are not plotted, as they are present in 
at least 99% of subjects. Furthermore KIR2DL5 is not plotted as KIR2DL5A is on the 
telomeric region and KIR2DL5B is on the centromeric LD region.  
 
 
